立体定向体部放疗治疗经前列腺特异性膜抗原正电子发射断层扫描检出的寡转移性前列腺癌
这项前瞻性单中心研究纳入2014年11月至2016年7月接受立体定向体部放疗的复发性寡转移性前列腺癌患者,转移灶经前列腺特异性膜抗原正电子发射断层扫描确认限于淋巴结或骨且未接受雄激素剥夺治疗。中位随访16个月,中位生化无病生存期为11个月,15个月时为31.9%,所有生化失败患者复查扫描均未见野内失败,无患者发生≥2级晚期毒性。作者结论为立体定向体部放疗局部控制率极高且毒性轻微,但多数患者在15个月内出现远处复发。
要点
- 57例患者接受立体定向体部放疗,中位随访16个月,中位生化无病生存期11个月。
- 15个月生化无病生存率为31.9%,生化失败患者复查均未见野内失败。
- 无患者发生≥2级晚期毒性,但多数患者15个月内出现远处复发。
核心结论
- 立体定向体部放疗实现了极高的局部控制率且毒性轻微,但多数患者在15个月内出现远处复发,且远处复发似乎不被已知预后因素预测。
研究设计与样本
- 前瞻性单中心研究,纳入2014年11月至2016年7月接受立体定向体部放疗的复发性前列腺癌患者,转移灶经前列腺特异性膜抗原正电子发射断层扫描确认限于淋巴结或骨且为1至3个、未接受雄激素剥夺治疗,共57例符合条件。
主要发现
- 50例(88%)曾接受根治性前列腺切除术,从根治性治疗至立体定向体部放疗的中位时间为5.6年。
- 共治疗73个病灶:44例有1个转移灶,13例有2或3个;37例(65%)仅有淋巴结转移,18例(31%)仅有骨转移。
- 中位生化无病生存期为11个月,15个月时生化无病生存率为31.9%。
- 所有生化失败患者(n=43)复查前列腺特异性膜抗原正电子发射断层扫描,均未见野内失败。
- 生化无病生存期不受诊断时前列腺特异性抗原、Gleason评分、诊断至立体定向体部放疗时间、部位(骨 vs 淋巴结)、立体定向体部放疗前前列腺特异性抗原倍增时间或转移灶数量的影响;立体定向体部放疗前前列腺特异性抗原低的患者失败似乎较少见。
关键数值与推荐
- 立体定向体部放疗方案:骨转移为20Gy/1次或24Gy/2次,淋巴结转移为50Gy/5次或30Gy/3次。
- 生化失败定义为立体定向体部放疗后前列腺特异性抗原达到最低值+0.2 ng/ml。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of oligometastatic prostate cancer (PCa) remains controversial, especially following the introduction of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging. OBJECTIVE: To assess whether stereotactic body radiotherapy (SBRT) provides a potential for cure in a selected group of patients with oligometastatic PCa in the PSMA-PET era. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, single-centre study of patients with oligometastatic PCa undergoing SBRT from November 2014 to July 2016. We included patients with relapsed PCa receiving SBRT with PSMA-PET-confirmed oligometastases (n=1-3) confined to lymph nodes (LNs) or bone without androgen deprivation therapy. SBRT schedules included 20Gy/1# or 24Gy/2# to bone metastases, and 50Gy/5# or 30Gy/3# to LNs. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was biochemical failure (BF) defined as a prostate-specific antigen (PSA) level of nadir + 0.2 ng/ml following SBRT. RESULTS AND LIMITATIONS: Fifty-seven patients were eligible, of whom 50 (88%) had undergone radical prostatectomy. The median time from definitive treatment to SBRT was 5.6 yr. A total of 73 lesions were treated: 44 patients had one metastasis, while 13 had two or three. Thirty-seven patients (65%) had LN-only disease, while 18 (31%) had bone-only metastasis. Median follow up was 16 mo. The median biochemical disease-free survival (bDFS) for the cohort was 11 mo, with 31.9% bDFS at 15 mo. All patients with BF (n=43) underwent a repeat PSMA-PET scan, which revealed no in-field failures. Median bDFS was not affected by prostate-specific antigen (PSA) at diagnosis, Gleason score, time from diagnosis to SBRT, site (bone vs LN), PSA doubling time before SBRT, or number of metastases. Failures were somewhat less common in patients with low PSA before SBRT. Toxicity was rare: no patients developed grade ≥2 late toxicity. CONCLUSIONS: SBRT delivered very high rates of local control with minimal toxicity. However, distant recurrences occurred in most patients by 15 mo and did not appear to be predicted by known prognostic factors. PATIENT SUMMARY: In this report, we looked at outcomes after the use of stereotactic body radiotherapy for patients with prostate cancer spread to one to three lymph nodes or bones as detected by positron emission tomography scans. We demonstrated high rates of control of the treated lesions with low toxicity, but by 15 mo more than two-thirds of patients had developed recurrent cancer outside the treated area.
引用
- Kneebone A, Hruby G, Ainsworth H, et al. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2018. PMID: 31158100. doi:10.1016/j.euo.2018.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。